SABCS15 Friday Press Conference
Dec 11, 2015•1 hr 7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Moderator: SABCS Co-director Kent Osborne, MD, director of the Dan L Duncan Cancer Center at Baylor College of Medicine
- T-DM1 Improved Overall Survival for Heavily Pretreated Patients With HER2-positive Breast Cancer;
- Phase III BELLE-2 Trial Meets Primary Endpoint of Progression-free Survival;
- No Significant Difference in Recurrence Rates Among Women With DCIS Taking Anastrozole or Tamoxifen; and
- DCIS Patients Receiving Anastrozole Reported Symptoms Different From Those Receiving Tamoxifen.
For the best experience, listen in Metacast app for iOS or Android